CL2008003383A1 - Compuestos derivados de (espiro piperidin)-benzamida, inhibidores del transportador equilibrativo de nucleosidos ent1; composicion farmaceutica que comprende uno de los compuestos; proceso para preparar la composicion; y proceso para preparar los compuestos, utiles para tratamientos del dolor agudo y cronico. - Google Patents

Compuestos derivados de (espiro piperidin)-benzamida, inhibidores del transportador equilibrativo de nucleosidos ent1; composicion farmaceutica que comprende uno de los compuestos; proceso para preparar la composicion; y proceso para preparar los compuestos, utiles para tratamientos del dolor agudo y cronico.

Info

Publication number
CL2008003383A1
CL2008003383A1 CL2008003383A CL2008003383A CL2008003383A1 CL 2008003383 A1 CL2008003383 A1 CL 2008003383A1 CL 2008003383 A CL2008003383 A CL 2008003383A CL 2008003383 A CL2008003383 A CL 2008003383A CL 2008003383 A1 CL2008003383 A1 CL 2008003383A1
Authority
CL
Chile
Prior art keywords
compounds
preparing
composition
pharmaceutical composition
benzamide
Prior art date
Application number
CL2008003383A
Other languages
English (en)
Inventor
Cleyn Michel Anna Jozef De
Jean-Paul René Marie André Bosmans
Didier Jean-Claude Berthelot
Serge Maria Aloysius Pieters
Bie Maria Pieter Verbist
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CL2008003383A1 publication Critical patent/CL2008003383A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)

Abstract

EL COMPUESTO DERIVADO DE (ESPIRO PIPERIDIN)-BENZAMIDA DE FORMULA (I) INCLUYENDO CUALQUIER FORMA ÉSTEREOQUÍMICAMENTE ISOMÉRICA DEL MISMO, EN DONDE -A-B-, R1 , R2, A3, A4, A5 Y R6 SE DEFINEN TAL COMO EN LA MEMORIA DESCRIPTIVA. UNA COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE UN PORTADOR FARMACÉUTICAMENTE ACEPTABLE Y UNA CANTIDAD<br /> TERAPÉUTICAMENTE ACTIVA DE DICHO COMPUESTO. UN PROCESO PARA PREPARAR UNA COMPOSICIÓN FARMACÉUTICA DONDE UNA CANTIDAD TERAPÉUTICAMENTE ACTIVA DE DICHO COMPUESTO SE MEZCLA CON UN PORTADOR FARMACÉUTICAMENTE ACEPTABLE. UN PROCESO PARA PREPARAR UN COMPUESTO DE FÓRMULA (I).
CL2008003383A 2007-11-14 2008-11-13 Compuestos derivados de (espiro piperidin)-benzamida, inhibidores del transportador equilibrativo de nucleosidos ent1; composicion farmaceutica que comprende uno de los compuestos; proceso para preparar la composicion; y proceso para preparar los compuestos, utiles para tratamientos del dolor agudo y cronico. CL2008003383A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07120630 2007-11-14

Publications (1)

Publication Number Publication Date
CL2008003383A1 true CL2008003383A1 (es) 2010-02-05

Family

ID=39145373

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008003383A CL2008003383A1 (es) 2007-11-14 2008-11-13 Compuestos derivados de (espiro piperidin)-benzamida, inhibidores del transportador equilibrativo de nucleosidos ent1; composicion farmaceutica que comprende uno de los compuestos; proceso para preparar la composicion; y proceso para preparar los compuestos, utiles para tratamientos del dolor agudo y cronico.

Country Status (18)

Country Link
US (1) US8263592B2 (es)
EP (1) EP2209790B1 (es)
JP (1) JP5369108B2 (es)
KR (1) KR101598136B1 (es)
CN (1) CN101855224B (es)
AR (1) AR069304A1 (es)
AU (1) AU2008322960B2 (es)
BR (1) BRPI0820642B1 (es)
CA (1) CA2704423C (es)
CL (1) CL2008003383A1 (es)
EA (1) EA017215B1 (es)
ES (1) ES2569511T3 (es)
HK (1) HK1146722A1 (es)
IL (1) IL205710A (es)
JO (1) JO3126B1 (es)
PA (1) PA8803401A1 (es)
TW (1) TWI437000B (es)
WO (1) WO2009062990A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201101959D0 (en) 2011-02-04 2011-03-23 Univ Nottingham Novel ether linked compoundsand improved treatments for cardiac and cardiovascular disease
AU2015279377B2 (en) 2014-06-26 2019-09-12 F. Hoffmann-La Roche Ag Indolin-2-one or pyrrolo-pyridin-2-one derivatives
CN108349942B (zh) 2015-11-06 2021-03-30 豪夫迈·罗氏有限公司 用于治疗cns和相关疾病的二氢吲哚-2-酮衍生物
WO2017076842A1 (en) * 2015-11-06 2017-05-11 F. Hoffmann-La Roche Ag Indolin-2-one derivatives
CA3002489C (en) 2015-11-06 2023-11-07 F.Hoffmann-La Roche Ag Indolin-2-one derivatives
CN105802999B (zh) * 2016-04-01 2019-05-03 中南大学湘雅医院 一种膜蛋白ENTs跨膜转运ODNs的试剂盒及方法
JP6879677B2 (ja) 2016-05-26 2021-06-02 株式会社クボタ 作業車
TW201817726A (zh) 2016-11-14 2018-05-16 大陸商江蘇恆瑞醫藥股份有限公司 ３，４－二吡啶基吡唑類衍生物、其製備方法及其在醫藥上的應用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9701396D0 (sv) * 1997-04-15 1997-04-15 Astra Pharma Prod Compounds
GB0003397D0 (en) * 2000-02-14 2000-04-05 Merck Sharp & Dohme Therapeutic agents
WO2004060902A2 (en) * 2002-12-31 2004-07-22 John K Buolamwini Novel nucleoside transport inhibitors
JPWO2004101593A1 (ja) * 2003-05-16 2006-07-13 キッセイ薬品工業株式会社 ５’−修飾ヌクレオシド誘導体及びその医薬用途
ES2377937T3 (es) * 2003-12-26 2012-04-03 Kissei Pharmaceutical Co., Ltd. Derivados de benzimidazol y usos médicos de los mismos
WO2007011815A2 (en) 2005-07-15 2007-01-25 Children's Hospital Medical Center Apparatus for minimally invasive posterior correction of spinal deformity
TW200804393A (en) * 2005-11-14 2008-01-16 Solvay Pharm Gmbh Novel N-sulfamoyl-N'-benzopyranpiperidines for medical use
US7576207B2 (en) * 2006-04-06 2009-08-18 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use

Also Published As

Publication number Publication date
BRPI0820642A2 (pt) 2020-08-11
US20100280025A1 (en) 2010-11-04
US8263592B2 (en) 2012-09-11
CA2704423C (en) 2017-01-10
BRPI0820642B1 (pt) 2021-05-25
WO2009062990A2 (en) 2009-05-22
IL205710A0 (en) 2010-11-30
AR069304A1 (es) 2010-01-13
ES2569511T3 (es) 2016-05-11
EA201070599A1 (ru) 2010-12-30
HK1146722A1 (en) 2011-07-08
CN101855224B (zh) 2012-11-28
WO2009062990A3 (en) 2009-09-24
CA2704423A1 (en) 2009-05-22
JP5369108B2 (ja) 2013-12-18
CN101855224A (zh) 2010-10-06
KR101598136B1 (ko) 2016-02-29
EA017215B1 (ru) 2012-10-30
JO3126B1 (ar) 2017-09-20
EP2209790B1 (en) 2016-02-17
EP2209790A2 (en) 2010-07-28
TW200936593A (en) 2009-09-01
JP2011503147A (ja) 2011-01-27
TWI437000B (zh) 2014-05-11
PA8803401A1 (es) 2009-06-23
AU2008322960A1 (en) 2009-05-22
KR20100089088A (ko) 2010-08-11
IL205710A (en) 2013-07-31
AU2008322960B2 (en) 2013-02-07

Similar Documents

Publication Publication Date Title
CL2008003383A1 (es) Compuestos derivados de (espiro piperidin)-benzamida, inhibidores del transportador equilibrativo de nucleosidos ent1; composicion farmaceutica que comprende uno de los compuestos; proceso para preparar la composicion; y proceso para preparar los compuestos, utiles para tratamientos del dolor agudo y cronico.
CL2009000394A1 (es) Compuestos derivados de n-(1h-indazol-5-il)pirrolidin-3-carboxamida sustituida, inhibidores de erk; composicion farmaceutica; y su uso en el tratamiento del cancer.
ES2546847T3 (es) Formulaciones de un inhibidor de la Src/Abl
CL2009000662A1 (es) Compuestos derivados de 1,2,4-triazol trisustituidos, moduladores del receptor de acetilcolina nicotinicos; composicion farmaceutica; su proceso de preparacion; y uso para la prevencion o el tratamiento de trastornos psicoticos, trastornos o enfermedades de daño intelectual, o enfermedades o trastornos inflamatorios.
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
MX2009003939A (es) Derivados de imidazolona e imidazolidinona como inhibidores de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1 para diabetes.
MX2010003224A (es) Derivados de biaril sulfonamida.
EA201690102A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
CR20140361A (es) Inhibidores de pde9 con estructura básica de imidazotriazinona
GEP20125487B (en) Organic compounds and their use
AR060631A1 (es) Derivados de pirimidina y su uso como inhibidores de fosfatidilnositol 3-quinasa (pi3k)
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
DOP2014000085A (es) Derivados de (4-fenilimidazol-2-il)etilamina útiles como moduladores de canal de sodio
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
PE20091556A1 (es) Derivado heterociclico fusionado y su uso
TW200616958A (en) New alkyl-pyridines as 11-beta inhibitors for diabetes
CL2011002706A1 (es) Compuestos derivados de 4-(1,3-oxazol-2-il)-1h-indazol; composicion farmaceutica que los comprende; y sus usos en el tratamiento de enfermedades tales como epoc, autoinmunes, asma, entre otras.
MX2009010567A (es) Derivados de imidazolidinona.
MX2007003546A (es) Derivados de indozolona como inhibidores de 11-beta- hidroxiesteroide-deshidrogenasa.
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
DOP2009000124A (es) Derivados de benzamida como receptores agonista ep4
MX353000B (es) Compuestos de pirazol como antagonistas de crth2.
NZ718514A (en) Compounds, compositions and methods useful for cholesterol mobilisation
AR062886A1 (es) Compuestos de tiazol pirazolopirimidina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento
MX2010002278A (es) Farmacos antivirales para el tratamiento de una infeccion por arenavirus.